Spurred by U.S. tax breaks, Amgen will build a $165 million next-generation biologics plant in West Greenwich, Rhode Island. More: Amgen names Rhode Island as location for its new U.S. next-gen biologics plant Source: fierce
read moreNovartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures. More: Novartis’ Afinitor Disperz wins new TSC-related approval Source: News
read moreAlexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. More: Alexion to buy Wilson for 5m Source: News
read moreIt is looking likely that another late-stage candidate for Alzheimer’s disease will fail to make it past Phase III trials, with vTv Therapeutics’ experimental therapy the latest in a long line to miss its targets. More: vTv reports Alzheimer’s candidate
read moreThe National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer. More: NICE no for Roche’s Alecensa Source: News
read moreEuropean regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU. More: EU regulators expand reach of Sobi’s Kineret
read more© 1994 - 2026 B.M. Pharmaceuticals